Refine by
Rheumatic Articles & Analysis
10 news found
On 28 October 2022, the PRAC recommended the harmonization of all labels and concluded that JAK inhibitors should remain indicated for the treatment of patients with RA who have responded inadequately to or who cannot tolerate disease modifying anti-rheumatic drugs (DMARDs) therapy, and for patients with UC who have responded inadequately to or who cannot tolerate conventional ...
Then SURUS should select articles about diabetes, but not about rheumatism. So we show SURUS a database containing lots and lots of articles, where we manually labelled the contents. ...
The results of ongoing and planned clinical studies may allow for rapidly broadening the development towards additional indications, such as cardiovascular diseases and rheumatic diseases other than systemic sclerosis. The company's owners include Industrifonden, Hadean Ventures, Linc, and a number of successful life science entrepreneurs. ...
Remedica becomes a strategic partner of the Join Rheuma Kids campaign by the Cyprus League against Rheumatism and on the occasion of the World Day of Youth Rheumatic Diseases, on the 18th of March, Remedica supported the campaign for children with rheumatic diseases. The campaign aims to inform the general public regarding the prevention, ...
These encouraging results support development of GS-248 as a treatment of systemic sclerosis and a range of other medical conditions, such as cardiovascular diseases and rheumatic diseases. The randomized, placebo-controlled, double-blind Phase II study will include approximately 80 patients at clinical sites in four European countries. ...
The trial will evaluate the safety and effectiveness of the SetPoint bioelectronic platform in patients with moderate-to-severe RA who are incomplete responders or are intolerant to biologic or targeted synthetic disease modifying anti-rheumatic drugs (DMARDs). “This is a significant milestone for SetPoint that will enable interactive communication with the FDA, priority ...
The trial will evaluate the safety and effectiveness of the SetPoint bioelectronic platform in patients with moderate-to-severe RA who are incomplete responders or are intolerant to biologic or targeted synthetic disease modifying anti-rheumatic drugs (DMARDs). “RA is a debilitating condition for patients, which without effective treatment, can result in long-term loss of ...
At the annual European congress of rheumatology meeting, The European League Against Rheumatism (EULAR), taking place in Amsterdam on June 13th-16th, leading investigators from United States, Israel, and Egypt will present new data on the 14-3-3η blood test. ...
Principal Investigator: Bongani Mayosi, University of Cape Town, South Africa The RHDGen Network: Genetics of rheumatic heart disease and molecular epidemiology of Streptococcus pyogenes pharyngitis 8. ...
” The findings appear online in the Jan. 11 issue of the Journal Arthritis and Rheumatism. Miller, who studies the causes of autoimmune diseases, explains that the body’s immune system makes large numbers of proteins called antibodies to help the body fight off infections. ...